Zevra Therapeutics (ZVRA) Invested Capital (2014 - 2023)

Zevra Therapeutics (ZVRA) posted Invested Capital of $37.7 million for Q4 2023, up 5419.77% on a QoQ basis from $683000.0 in Q1 2021.

Zevra Therapeutics (ZVRA) Invested Capital (2014 - 2023) Analysis & Trends

Zevra Therapeutics' Invested Capital history runs 5 years deep, the most recent figure standing at $37.7 million for Q4 2023.

  • Quarterly Invested Capital changed N/A year-over-year to $37.7 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $37.7 million (changed N/A YoY) and the FY2023 annual result came in at $37.7 million, changed N/A from the prior year.
  • Invested Capital was $37.7 million for Q4 2023 at Zevra Therapeutics, up from $683000.0 in the prior quarter.
  • Across five years, Invested Capital topped out at $37.7 million in Q4 2023 and bottomed at $390000.0 in Q4 2020.
  • A 3-year average of $12.9 million and a median of $683000.0 in 2021 frame the typical range for Invested Capital.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.96 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 116.14 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Zevra Therapeutics 239.71 Mn 39.10 Mn 34.32 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 37.70 Mn
Mar 31, 2021 683,000.00
Dec 31, 2020 390,000.00
Dec 31, 2015 2.04 Mn
Sep 30, 2015 1.63 Mn
Dec 31, 2014 482,000.00